wasn't IMVEXXY the largest revenue contributor in the portfolio? I remember (if my memory was still good because that was about 2 years ago...) a medical analyst wrote around that time, saying IMVEXXY is the main asset while some others in the portfolio are just not selling, can even been considered as nothing or burden. I don't have the sales figure roboshan, but if you have that breakup showing IMVEXXY is only small part then I am wrong.
MYX Price at posting:
$3.95 Sentiment: None Disclosure: Not Held
